Skip to content
Biodatica
Start free

Eli Lilly and Company

Miami, Florida

OncologyPhase IIIListed · LLY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

yesterdayTrial registeredJul 17, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Feb 10, 2026

    Overweight, Obesity · RECRUITING · sponsor: Eli Lilly and Company · A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

    ClinicalTrials.gov · NCT07392190 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Feb 9, 2026

    Osteoarthritis, Overweight or Obesity · RECRUITING · sponsor: Eli Lilly and Company · Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

    ClinicalTrials.gov · NCT07353931 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Dec 29, 2025

    Type 2 Diabetes Mellitus (T2DM) · ACTIVE_NOT_RECRUITING · sponsor: Eli Lilly and Company · A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus

    ClinicalTrials.gov · NCT07313813 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Aug 6, 2025

    Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Esophageal Neoplasms · RECRUITING · sponsor: Eli Lilly and Company · A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    ClinicalTrials.gov · NCT07114601 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Jul 13, 2023

    Healthy, Hepatic Insufficiency · COMPLETED · sponsor: Eli Lilly and Company · A Study of LY3437943 in Participants With Impaired and Normal Liver Function

    ClinicalTrials.gov · NCT05916560 (opens the source filing in a new tab)

  6. Trial

    PHASE1 registered

    Jun 13, 2023

    Healthy, Hepatic Insufficiency · COMPLETED · sponsor: Eli Lilly and Company · A Study of LY3502970 in Participants With Impaired and Normal Liver Function

    ClinicalTrials.gov · NCT05882032 (opens the source filing in a new tab)

  7. Trial

    PHASE1 registered

    May 17, 2022

    Healthy · COMPLETED · sponsor: Eli Lilly and Company · A Study of Two Different Formulations of LY3502970 in Healthy Participants

    ClinicalTrials.gov · NCT05341089 (opens the source filing in a new tab)

  8. Trial

    PHASE1 registered

    Dec 10, 2018

    Healthy, Hepatic Impairment · COMPLETED · sponsor: Eli Lilly and Company · A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

    ClinicalTrials.gov · NCT05436912 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources